Patient No | Age (years) | Sex | Chemo | p53/i | p53/R | mdm2/i | mdm2/R | EGFR/i | EGFR/R | msh2/i | msh2/R | PFST | TST |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
*Last contact; †result not available or data not known. | |||||||||||||
/i, immunohistochemical expression in initial tumours; /R, immunohistochemical expression in recurrent lesions; Chemo, chemotherapy; PFST, progression-free survival time; TST, total survival time. | |||||||||||||
1 | 65 | Male | Yes | 61% | 19% | 9% | 15% | + | + | 56% | 50% | 163 | 273 |
2 | 73 | Male | Yes | 36% | 4% | 5% | 17% | + | − | 53% | 32% | 198 | 279* |
3 | 66 | Male | No | 11% | 31% | 60% | 0% | + | − | 88% | 61% | 194 | 556 |
4 | 60 | Female | No | 73% | 8% | 17% | 16% | + | − | 32% | 55% | 157 | 157* |
5 | 64 | Female | No | 56% | 12% | 27% | 17% | + | − | 82% | 63% | 146 | 189 |
6 | 66 | Female | Yes | 26% | 10% | 11% | 39% | + | + | 68% | 45% | 98 | 399 |
7 | 62 | Female | Yes | 14% | 3% | 15% | 51% | + | ++ | 75% | 45% | † | † |
8 | 63 | Male | Yes | 18% | 3% | 10% | 1% | − | − | 66% | 59% | 131 | 819 |
9 | 63 | Male | No | 14% | 35% | 18% | 39% | + | − | 54% | 45% | 63 | 298 |
10 | 56 | Female | Yes | 23% | 9% | 19% | 2% | + | ++ | 24% | 57% | 270 | 1109 |
11 | 50 | Male | No | 67% | 14% | 17% | 13% | + | − | 58% | 60% | 604 | 620 |
12 | 51 | Male | no | 36% | 12% | 15% | 6% | + | − | 67% | 40% | 635 | 1113 |
13 | 47 | Male | Yes | 33% | 11% | 2% | 1% | + | − | 71% | 51% | 99 | 255 |
14 | 58 | Male | Yes | 44% | 31% | 5% | 1% | + | + | 69% | 37% | 82 | 293 |
15 | 59 | Male | Yes | 39% | 0% | 8% | 1% | + | † | 82% | 51% | 238 | 321 |
16 | 53 | Male | Yes | 21% | 30% | 15% | 19% | − | − | 71% | 52% | 89 | 305 |
17 | 50 | Male | Yes | 65% | 12% | 3% | 12% | + | + | 72% | 47% | 105 | 439 |
18 | 55 | Male | Yes | 21% | 0% | 22% | 31% | + | − | 65% | 59% | 151 | 424 |
19 | 29 | Female | Yes | 0% | 39% | 17% | 0% | + | − | 63% | 46% | 248 | 433 |
20 | 29 | Female | Yes | 48% | 0% | 5% | 10% | + | ++ | 71% | 45% | 426 | 738 |
21 | 32 | Male | No | 34% | 13% | 1% | 7% | + | − | 75% | 74% | 86 | 1495 |
22 | 39 | Female | Yes | 32% | 56% | 10% | 3% | + | + | 43% | 57% | 248 | 561 |
23 | 63 | Female | No | 1% | 27% | 12% | 0% | − | − | 36% | 58% | 139 | 309 |
24 | 58 | Female | Yes | 0% | 33% | 9% | 5% | + | ++ | 23% | 46% | 190 | 400* |
25 | 50 | Male | Yes | 53% | 27% | 18% | 35% | + | − | 22% | 64% | † | 353 |
26 | 46 | Male | No | 11% | 17% | 1% | 7% | + | + | 62% | 42% | 200 | 541 |
27 | 49 | Male | No | 8% | 0% | 13% | 4% | + | + | 66% | 42% | 152 | 383 |